^
Association details:
| Biomarker: | PAK4 deletion |
|---|---|
| Cancer: | Prolymphocytic Leukemia |
| Drug: | Campath (alemtuzumab) (CD52 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Subsequently, he was transitioned to alemtuzumab consolidation and completed 11 weeks of therapy with sustained haematologic response. However, progressive disease was noted with increased lymphadenopathy on positron emission tomography/computed tomography (PET‐CT) and CT scans. Left inguinal node and bone marrow biopsies confirmed disease involvement. Molecular evaluation by next generation sequencing (FoundationOne Heme panel) on the lymph node tissue demonstrated BRAF V600E, ATM D2721N, CDKN2A/B loss, RAD50 Y625, STAT5B N642H and TCL1A rearrangement.
DOI:
10.1111/bjh.16992
